Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Medmira (TSV: MIR )

0.1350 +0.0050 (+3.85%)
Streaming Delayed Price Updated: 1:59 PM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 99,280
Open 0.1300
Bid (Size) 0.1300 (1,450)
Ask (Size) 0.1350 (1,075)
Prev. Close 0.1300
Today's Range 0.1250 - 0.1350
52wk Range 0.0700 - 0.1350
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications
Via ACCESS Newswire
MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use
Via ACCESSWIRE

Performance

YTD
+22.73%
+22.73%
1 Month
+80.00%
+80.00%
3 Month
+68.75%
+68.75%
6 Month
+68.75%
+68.75%
1 Year
+35.00%
+35.00%

More News

Read More
MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
Via ACCESSWIRE
MedMira Reports First Quarter Results FY2025
Via ACCESSWIRE
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
Via ACCESSWIRE
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
Via ACCESSWIRE
MedMira Announces the appointment of Vice President of Commercial Operations
Via ACCESSWIRE
MedMira Reports Third Quarter Results FY2024
Via ACCESSWIRE
MedMira Announces the Hire of Vice President of Business Development
Via ACCESSWIRE
Clinical Trials to get Underway with Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada
Via ACCESSWIRE
MedMira Reports Second Quarter Results FY2024
Via ACCESSWIRE
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
Via ACCESSWIRE
CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products
Via ACCESSWIRE
Corporate Update on Clinical Evaluation of MedMira’s Products
Via ACCESSWIRE
MedMira Reports First Quarter Results FY2024
Via ACCESSWIRE
MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
Via ACCESSWIRE
Progress Update on Securities
Via ACCESSWIRE
MedMira Reports Third Quarter Results FY2023
Via ACCESSWIRE
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
Via ACCESSWIRE
Update on MedMira’s Regulatory Path in Canada and the USA
Via ACCESSWIRE
MedMira Reports Second Quarter Results FY2023
Via ACCESSWIRE
Update on MedMira’s Reveal TP (Syphilis) Clinical Trials in Canada
Via ACCESSWIRE
MedMira Enters into Partnership with Maternova for USA and Latin America
Via ACCESSWIRE
Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis
From Maternova, Inc.
Via Business Wire
MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.